Mylan’s Generic Advair Delay Gives Leverage To Rivals
Executive Summary
Mylan received a “complete response” letter from FDA on its application for a generic version of GSK’s blockbuster Advair, offering scarce details on the reason why or possible length of the delay.
You may also be interested in...
Mylan Sees Generic Advair Marathon Nearing FDA Finish Line
Company management expressed confidence its application for the first generic Advair is approvable, although the US agency didn’t clear it in October as Mylan had hoped.
Mylan Sees Generic Advair Marathon Nearing FDA Finish Line
Company management expressed confidence its application for the first generic Advair is approvable, although the US agency didn’t clear it in October as Mylan had hoped.
Branded Advair Breathes Another Day; Mylan Says A CRL Is On The Way For A Generic
FDA alerted Mylan to expect a complete response letter related to its ANDA for generic Advair. The company said it still could receive an approval prior to the standard 90-day time period after responding to the letter, because the application has a priority designation.